Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Depreciation (2018 - 2024)

Bicycle Therapeutics (BCYC) has disclosed Accumulated Depreciation for 7 consecutive years, with $16.6 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Accumulated Depreciation changed N/A year-over-year to $16.6 million, compared with a TTM value of $16.6 million through Jun 2024, changed N/A, and an annual FY2023 reading of $13.4 million, up 70.33% over the prior year.
  • Accumulated Depreciation was $16.6 million for Q2 2024 at Bicycle Therapeutics, up from $14.9 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $16.6 million in Q2 2024 and bottomed at $4.0 million in Q4 2020.
  • Average Accumulated Depreciation over 5 years is $8.6 million, with a median of $6.3 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation rose 19.05% in 2021, then soared 70.33% in 2023.
  • Year by year, Accumulated Depreciation stood at $4.0 million in 2020, then grew by 19.05% to $4.8 million in 2021, then skyrocketed by 63.81% to $7.9 million in 2022, then surged by 70.33% to $13.4 million in 2023, then rose by 23.99% to $16.6 million in 2024.
  • Business Quant data shows Accumulated Depreciation for BCYC at $16.6 million in Q2 2024, $14.9 million in Q1 2024, and $13.4 million in Q4 2023.